DDW 2024: Rates of Clinical Remission, Endoscopic Response High With Mirikizumab in Moderate-to-Severe Crohn Disease
Remission rate at week 52 higher for mirikizumab versus ustekinumab and placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.